These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22668246)

  • 1. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?
    Attard A; Taylor DM
    CNS Drugs; 2012 Jun; 26(6):491-508. PubMed ID: 22668246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.
    Foussias G; Remington G
    Can J Psychiatry; 2010 Mar; 55(3):117-25. PubMed ID: 20370961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
    Naber D; Lambert M
    CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
    Nasrallah HA
    J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer atypical antipsychotic medication versus clozapine for schizophrenia.
    Tuunainen A; Wahlbeck K; Gilbody SM
    Cochrane Database Syst Rev; 2000; (2):CD000966. PubMed ID: 10796559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.
    Haro JM; Salvador-Carulla L
    CNS Drugs; 2006; 20(4):293-301. PubMed ID: 16599647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
    Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
    Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotics and metabolics in the post-CATIE era.
    Meyer JM
    Curr Top Behav Neurosci; 2010; 4():23-42. PubMed ID: 21312396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone versus other atypical antipsychotic medication for schizophrenia.
    Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
    Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zotepine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006628. PubMed ID: 20091601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New generation antipsychotics for first episode schizophrenia.
    Rummel C; Hamann J; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.